Drug Information

Drug (ID: DG01470) and It's Reported Resistant Information

• Name: Amiloride
• Synonyms: AMILORIDE; Amipramidin; 2609-46-3; Midamor; Guanamprazine; Amipramizid; Amipramizide; Guanamprazin; Amilorida; 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; Amiloridum; Amyloride; Amiloridum [INN-Latin]; Amilorida [INN-Spanish]; N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid; UNII-7DZO8EB0Z3; 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide; 3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide; MK-870; Amiloride hydrochloride hydrate; CHEMBL945; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-; 7DZO8EB0Z3; CHEBI:2639; N-amidino-3,5-diamino-6-chloro-2-pyrazinecarboxamide; 137053-86-2; NCGC00015089-08; Amiloride [INN:BAN]; AMIPRAMIDINE; DSSTox_CID_23853; DSSTox_RID_80077; DSSTox_GSID_43853; Amiclaran; C6H8ClN7O; Amiclaran (TN); Amiloride (INN); CAS-2609-46-3; CCRIS 6545; EINECS 220-024-7; AmilorideHCl; Amikal (Hydrochloride dihydrate); Midamor (Hydrochloride dihydrate); MK-870 (Hydrochloride dihydrate); Spectrum_000034; Tocris-0890; 1f5l; Prestwick0_000007; Prestwick1_000007; Prestwick2_000007; Prestwick3_000007; Spectrum2_000118; Spectrum3_000293; Spectrum4_000132; Spectrum5_000776; Lopac-A-7410; Lopac0_000111; SCHEMBL27562; BSPBio_000013; BSPBio_001572; BSPBio_001826; KBioGR_000292; KBioGR_000544; KBioSS_000292; KBioSS_000394; MLS001060798; BIDD:GT0466; DivK1c_000182; SPBio_000136; SPBio_001934; BPBio1_000015; GTPL2421; DTXSID9043853; BCBcMAP01_000101; BDBM16173; KBio1_000182; KBio2_000292; KBio2_000394; KBio2_002860; KBio2_002962; KBio2_005428; KBio2_005530; KBio3_000583; KBio3_000584; KBio3_001326; NINDS_000182; Bio1_000359; Bio1_000848; Bio1_001337; Bio2_000292; Bio2_000772; HMS1791O14; HMS1989O14; HMS2089H05; HMS2213E05; HMS3355K04; ACT05635; ACT05652; BCP16815; HY-B0285; ZINC4340269; Tox21_110080; 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide; BBL028157; STL373007; AKOS015961348; Tox21_110080_1; CCG-204206; DB00594; MCULE-5948863568; SB74937; SDCCGSBI-0050099.P005; IDI1_000182; IDI1_034042; NCGC00015089-01; NCGC00015089-02; NCGC00015089-03; NCGC00015089-04; NCGC00015089-05; NCGC00015089-06; NCGC00015089-07; NCGC00015089-09; NCGC00015089-11; NCGC00015089-12; NCGC00015089-13; NCGC00015089-14; NCGC00015089-15; NCGC00015089-16; NCGC00015089-17; NCGC00015089-24; NCGC00024443-02; NCGC00024443-05; NCGC00024443-06; NCGC00024443-07; NCGC00024443-09; AC-13631; LS-13128; SMR000486264; U460; (3,5-Diamino-6-chloropyrazinoyl)guanidine; SBI-0050099.P004; N-amidino-3,5-diamino-6-chloropyrazinamide; AB00053415; FT-0703177; C06821; D07447; AB00053415-24; AB00053415-25; AB00053415_26; AB00053415_27; AB00053415_28; 609A463; Q419995; J-016249; BRD-K97181089-003-02-3; BRD-K97181089-310-03-0; N-amidino 3,5-diamino-6-chloro-2-pyrazinecarboxamide; F2173-0531; N-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-guanidine; 3,5-diamino-N-carbamimidoyl-6-chloro-pyrazine-2-carboxamide; 3,5-diamino-6-chloro-N-(diaminomethylene)pyrazinamide;hydrochloride
• Indication:
  In total 1 Indication(s)
  Head and body lice [ICD-11: 1G00]; Approved; [1]
• Target: Matrix metalloproteinase (MMP); NOUNIPROTAC; [1]
• Formula: 1
• IsoSMILES: C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N
• InChI: InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)
• InChIKey: XSDQTOBWRPYKKA-UHFFFAOYSA-N
• PubChem CID: 16231
• ChEBI ID: CHEBI:2639
• TTD Drug ID: D5IS6V
• INTEDE ID: DR00207
• DrugBank ID: DB00594

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Adrenal adenoma [ICD-11: 2F3Z]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: G protein-activated inward rectifier potassium channel 4 (GIRK4) [1]

• Sensitive Disease: Adrenal adenoma [ICD-11: 2F3Z.0]
• Molecule Alteration: Missense mutation; p.L168R (c.503T>G)
• Experimental Note: Identified from the Human Clinical Data

References

• Ref 1: Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosterone-producing adenomasEndocrinology. 2014 Apr;155(4):1353-62. doi: 10.1210/en.2013-1944. Epub 2014 Feb 7.